Adding ribociclib, a CDK*4/6 inhibitor, to NSAI** and goserelin improves progression-free survival (PFS) in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), according to the MONALEESA-7*** study presented at ESMO Asia 2018.
Treatment with the tyrosine kinase inhibitor cabozantinib led to improved tumour response, in terms of target lesion regression, alpha-fetoprotein (AFP) response, and time to disease progression compared with placebo in patients with advanced hepatocellular carcinoma (HCC) who had prior treatment with sorafenib, according to the CELESTIAL* trial presented at ESMO Asia 2018.
The addition of atezolizumab to standard of care (SOC) carboplatin and etoposide appears to improve overall survival (OS) and progression-free survival (PFS) in patients with extensive stage small cell lung cancer (ES-SCLC), setting in place a potential new SOC, according to the IMpower133* trial findings.
Stereotactic body radiotherapy (SBRT) is associated with significantly lower rates of acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in Asian patients with early-stage localized prostate cancer.
Ceritinib is a cost-effective first-line treatment option for patients with ALK-positive advanced non-small-cell lung cancer (NSCLC) in Hong Kong compared with crizotinib, according to results of a study reported at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.
The addition of the immune checkpoint inhibitor atezolizumab to standard-of-care (SoC) consisting of bevacizumab and chemotherapy in the first-line setting prolonged progression-free survival (PFS) and overall survival (OS) in individuals with non-squamous non-small-cell lung cancer (NSCLC) who were positive for EGFR* mutations, according to the IMpower150** trial presented at ESMO Asia 2018.
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.